Escolar Documentos
Profissional Documentos
Cultura Documentos
E
+9'1.22 6606 1000
+91,22 56061200
info@ajantapharma.com
lndia W www.ajantapharma.com
3'd May,2O17
Dear Sir,
We refer to the Audited financial results for the year ended 31"1 March, 2017 submitted
to your office today.
Kindly take the same on your records and disseminate to your members.
Thanking You,
Yours faithfully,
FoT AJANTA PHARMA LIMITED
/')
-'C/*
GAURANG SHAH
AVP - Legal &
Company Secretary
Encl.: a/a
India Exports
Improved rankings Rupee appreciation hurting
Cardiology
Specialty Ophthalmology
Segment
Dermatology
Pain Management
14 Divisions
Focused 3,000+ MRs
Marketing
200+ Products
About 70% products First to Market
8%
11%
8 9 6 7
Q4 FY 2016 Q4 FY 2017
Institution 35 21 -40%
FY 2016 FY 2017
Total 549 614 12%
22%
16% 16%
16%
11%
11%
9% 10%
8% 8%
36%
29%
26%
23%
16%
14%
12%
10% 10%
9%
Ophthal 4 5 28
Derma 13 13 98
Cardio 19 20 38
Pain 45 45 NA
Ajanta 33 33 88
South East
Asia
(3 Countries)
India
Africa
(19 Countries)
ANDA Status
Approval : Final 17, Tentative - 2
Under approval : 15
Filed in FY 2017 : 8
Filing target for FY 2018 : 12 to 15
Products
Products
5 2 2
Rs. cr.
Q4 FY 2016 Q4 FY 2017 Gth
Q4 FY 2016 Q4 FY 2017
Africa 174 132 -24%
Asia 119 137 15%
USA 5 45 838%
Others 2 2 34%
Source: Company
Total 300 317 6%
14 10 5
FY 2016 FY 2017
Rs. cr.
FY 2016 FY 2017 Gth
FY 2016 FY 2017
Africa 692 712 3%
Asia 461 417 -10%
USA 14 185 1179%
Others 10 5 -47%
Source: Company Total 1,178 1,319 12%
Formulation Manufacturing
3 existing facilities in Aurangabad, Maharashtra (1 USFDA & WHO Pre-Q approved)
1 Facility at Mauritius
Dahej (Gujarat) - Commercial operation began in April 2017 (US FDA inspection complete)
Guwahati (Assam) First phase commissioned, 2nd phase by Q4 FY 2018
API Manufacturing
1 Facility at Waluj (Aurangabad) - Captive Consumption
6%
106
5% R&D
4% 70 Focus
4% 50
37
Adding Team Adding
Capacity
800+ Scientistes 2 more location
Bio equivalence
FY 2013 FY 2014 FY 2015 FY 2016 FY 2017
(Rs. Cr.)
(Rs. Cr.)
Q4 Year ended
FY 2017 FY 2016 FY 2017 FY 2016
Income from Operations 477 431 2,002 1,749
Other Income 6 1% 5 1% 24 1% 21 1%
Finance Cost 1 0% 1 0% 3 0% 5 0%
Depreciation 19 4% 11 3% 61 3% 44 3%
Other Expenses 151 32% 125 29% 603 30% 492 28%
Total expenses 339 71% 302 70% 1,377 69% 1,212 69%
Profit before tax 144 30% 134 31% 648 32% 559 32%
Net Profit 114 24% 109 25% 507 25% 416 24%
(Rs. cr. )
Reserve
Profit Reconciliation
Particulars Reconciliation
Q4 FY 2016 FY 2016 FY 2016
Net Profit/Other Equity as per
106.31 401.41 1,154.37
Previous Indian GAAP
Fair Value of Financial Assets 1.60 4.45 10.38
Employee Benefits Actuarial
0.19 0.35 -
Gain/(Loss)
Deferred Tax (0.61) 2.95 8.42
Consolidated Total Income PAT (Rs. cr.) & PAT Margin (%)
(Rs. cr.)
12% 19% 21% 24% 25%
2,026 507
1,771
416
1,502
1,230 310
942 234
112
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
RONW ROCE
(%)
(%)
47% 50%
43% 45% 44%
40% 37% 41%
37%
32%
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
60 63 65 61
0.22
0.09
0.07
0.00
2013 2014 2015 2016 2017 2013 2014 2015 2016 2017
59
99 94
48
43 40 85 82
40
This presentation may include certain forward looking statements, based on current expectations, forecasts
and assumptions within the meaning of applicable laws and regulations. They are subject to risks and
uncertainties which could cause actual outcomes and results to differ materially from these statements.
The Company disclaims any obligation to revise any forward-looking statements. The readers may use their own
judgment and are advised to make their own calculations before deciding on any matter based on the
information given herein.
This material is used during oral presentation; it is not a complete record of the discussion.